Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
106 hedge funds and large institutions have $819M invested in Y-mAbs Therapeutics in 2020 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 42 increasing their positions, 38 reducing their positions, and 13 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 38
0.04% more ownership
Funds ownership: 53.53% → 53.57% (+0.04%)
3% less funds holding
Funds holding: 109 → 106 (-3)
11% less capital invested
Capital invested by funds: $920M → $819M (-$100M)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$13M |
| 2 |
Goldman Sachs
New York
|
+$5.82M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$4.55M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$3.95M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$15.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.8M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$7.04M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$3.67M |
| 5 |
Two Sigma Investments
New York
|
-$2.2M |
YMAB Hedge Fund Activity: Q3 2020 in Review
106 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q3 2020, worth a combined $819M — down 11% from $920M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of YMAB and 10 opened new positions — a net loss of 3 holders — while 38 trimmed existing stakes and 42 added.
The largest buyer was Wellington Management Group, adding an estimated $13M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $15.4M sold.
- 106 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q3 2020, down from 109 in Q2 2020.
- Funds reported $819M of Y-mAbs Therapeutics stock for Q3 2020, down 11% quarter-over-quarter.
- 10 funds opened new Y-mAbs Therapeutics positions in Q3 2020 and 13 closed out, a net change of -3 holders.
- The largest Y-mAbs Therapeutics buyer in Q3 2020 was Wellington Management Group, an estimated $13M added.
- The largest Y-mAbs Therapeutics seller in Q3 2020 was Perceptive Advisors, an estimated $15.4M sold.
Based on aggregated 13F filings for Q3 2020.